Chengda Biotechnology
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Chengda Biotechnology - overview
Established
2002
Location
Shenyang, Liaoning, China
Primary Industry
Biotechnology
About
Established in 2002 and based in Liaoning, China, Chengda Biotechnology operates as a biotechnology company that focuses on rabies vaccine production. The company provides vaccine production. The product of the company includes human rabies vaccine, veterinary rabies vaccine and human JE inactivated vaccine.
Current Investors
JD Capital, EBI Investment, New Alliance Capital
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.cdbio.cn
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Chengda Biotechnology - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 984,514,759.7 | 851,079,719 | 937,070,175 | 943,415,137.9 | 1,029,679,770.7 | 1,276,039,798.6 | 1,390,571,894.3 | - | - | - |
| % Revenue Growth (YoY) | - | (13.6%) | 10.1% | 0.7% | 9.1% | 23.9% | 9.0% | - | - | - |
| EBITDA (USD) | - | 526,485,994.9 | 568,391,742.1 | 587,257,125.6 | 616,066,922.7 | 720,254,107.2 | 746,639,396.3 | - | - | - |
| Operating Income (USD) | 575,000,656.3 | 473,039,030 | 501,822,450.1 | 521,056,121 | 548,340,276.3 | 672,954,174.2 | 693,521,581.9 | - | - | - |
| Operating Margin | 58.4% | 55.6% | 53.6% | 55.2% | 53.3% | 52.7% | 49.9% | - | - | - |
| % EBITDA Margin | - | 61.9% | 60.7% | 62.2% | 59.8% | 56.4% | 53.7% | - | - | - |
| NET Income (USD) | 495,804,276.4 | 404,088,258 | 442,496,071.7 | 457,707,513.4 | 457,082,832.5 | 555,862,116.3 | 612,871,721.3 | - | - | - |
| % Net Margin | 50.4% | 47.5% | 47.2% | 48.5% | 44.4% | 43.6% | 44.1% | - | - | - |
Chengda Biotechnology - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A | Completed | Shanghai BravoBio Co., Ltd. | - | ||||||||
| IPO | Completed | Chengda Biotechnology | - | ||||||||
| Unspecified Round | Completed | Chengda Biotechnology | - | ||||||||
| Unspecified Round | Completed | Chengda Biotechnology | - | ||||||||
| Unspecified Round | Completed | Chengda Biotechnology | - |
Displaying 1 - 5 of 8
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.